Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

 Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

Shots:

  • The P-III HAVEN (1,2,3, & 4) studies involve assessing of Hemlibra in patients with hemophilia A with/out factor VIII inhibitors resulted in zero treat bleeds @83wks., 87% with no treated joint bleeds, 92% with no spontaneous bleeds @25wks., improvement in QoL
  • The P-IIIb STASEY study reinforces safety profile of Hemlibra in 88 patients with hemophilia A with factor VIII inhibitors aged ≥12 yrs. characterized in the HAVEN 1 clinical study resulted in no thrombotic microangiopathy with no new safety signals
  • Hemlibra is a bispecific factor IXa & X directed Ab, activating the natural coagulation cascade and restoring the blood clotting process in patients with hemophilia A with/without factor VIII inhibitor and has received approval in 70+/40+ countries respectively

Click here to read full press release/ article | Ref: Roche | Image: New Dimension Exhibition Stands

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post